bioMérieux S.A. (EPA:BIM)

Market Cap	14.01B
Revenue (ttm)	3.98B
Net Income (ttm)	432.20M
Shares Out	117.93M
EPS (ttm)	3.64
PE Ratio	32.64
Forward PE	26.17
Dividend	0.90 (0.75%)
Ex-Dividend Date	Jun 9, 2025

Volume	94,224
Average Volume	107,580
Open	119.90
Previous Close	119.70
Day's Range	118.50 - 120.50
52-Week Range	88.25 - 122.50
Beta	0.48
RSI	47.79
Earnings Date	Sep 4, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.